RapidAI has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its AngioFlow perfusion imaging solution.

The AngioFlow by RapidAI technology facilitates clinical decision-making during neuro-interventional procedures by providing qualitative perfusion maps that indicate ischemic changes in the brain.

Designed for care teams in the interventional suite, AngioFlow by RapidAI leverages deep clinical AI to produce perfusion imaging analysis.

This facilitates the assessment of cerebral blood flow in brain regions, offering insights within minutes. The solution is set to bolster workflow efficiency and potentially improve patient outcomes.

The FDA-cleared module is expected to streamline operations and add financial value by minimising redundant imaging and potentially reducing the time spent on patient care.

It enables physicians at referring facilities to determine the necessity of additional scans, expediting clinical decisions and curtailing unnecessary imaging.

This feature benefits rural facilities and extensive hospital networks, where patient transfers between facilities can be time-consuming.

RapidAI CEO Karim Karti said: “We are pleased to expand our stroke AI imaging portfolio, the broadest in the industry, to include this new module. With AngioFlow by RapidAI, we can now support stroke AI imaging along the entire patient pathway, from the initial non-contrast CT scan all the way to the interventional suite.

“Already registered and used in Japan and Europe, we believe this technology will make a significant difference in the lives of US stroke patients.”

Last July, RapidAI raised $75m in Series C funding to enhance the innovation of its clinical decision and workflow support technology.